Thyme Companies launched Thyme Therapeutics, a new business focused on reducing the cost of oncology drugs through the commercialization of biosimilars.
The company plans to work with oncologists, health plans, and manufacturers to increase adoption of lower-cost cancer treatments.
Thyme Therapeutics is designed to address pricing volatility and incentive misalignment that can prevent biosimilar competition from translating into predictable savings for patients and healthcare organizations.
The company plans to launch its first asset in 2027.
Thyme Therapeutics is currently working with oncology groups, biosimilar manufacturers, and health plans as it develops its initial portfolio.
The launch comes as several major oncology biologics approach loss of exclusivity.
U.S. oncology drug spending reached approximately $84 billion in 2025, representing an increase of roughly 20% in one year.
Thyme Therapeutics believes broader and more durable adoption of biosimilars could significantly reduce spending as additional oncology drugs lose exclusivity.
The new company is the first business launched by Thyme Companies since the parent organization was formed in September 2026 alongside a Series E financing.
Thyme Companies was created to build separate businesses addressing different challenges across cancer care.
The organization is anchored by Thyme Care, an oncology care company focused on improving the cancer care experience and reducing costs.
KEY QUOTES:
“Few challenges in oncology are more urgent to solve right now than the rising cost of cancer drugs. With Thyme Therapeutics, we have an opportunity to rethink how value moves through the system so that more of the savings created by biosimilars can ultimately benefit patients and the healthcare system as a whole.”
Robin Shah, Executive Chairman of Thyme Companies
